{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:00:00Z","timestamp":1790449200743,"version":"4.1.0"},"reference-count":81,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arrhythm Electrophysiol Rev"],"abstract":"<jats:p>Cardiovascular disease and cancer are the leading causes of morbidity and mortality in the US. Despite the significant progress made in cancer treatment leading to improved prognosis and survival, ventricular arrhythmias (VA) remain a known cardiovascular complication either exacerbated or induced by the direct and indirect effects of both traditional and novel cancer treatments. Although interruption of cancer treatment because of VA is rarely required, knowledge surrounding this issue is essential for optimising the overall care of patients with cancer. The mechanisms of cancer-therapeutic-induced VA are poorly understood. This review will discuss the ventricular conduction (QRS) and repolarisation abnormalities (QTc prolongation), and VAs associated with cancer therapies, as well as existing strategies for the identification, prevention and management of cancer-treatment-induced VAs.<\/jats:p>","DOI":"10.15420\/aer.2023.04","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T13:49:46Z","timestamp":1685454586000},"source":"Crossref","is-referenced-by-count":22,"title":["Ventricular Arrhythmia in Cancer Patients: Mechanisms, Treatment Strategies and Future Avenues"],"prefix":"10.15420","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0549-9440","authenticated-orcid":false,"given":"Manyoo A","family":"Agarwal","sequence":"first","affiliation":[{"name":"Heart, Vascular and Thoracic Institute, Cardio-Oncology Program, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1834-8147","authenticated-orcid":false,"given":"Aadhavi","family":"Sridharan","sequence":"additional","affiliation":[{"name":"Section of Electrophysiology, Division of Cardiology, Department of Medicine, Banner Health, University of Arizona \u2013 Tucson, Tucson, AZ, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4853-519X","authenticated-orcid":false,"given":"Rhea C","family":"Pimentel","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, University of Kansas Health System, Kansas City, KS, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3401-8933","authenticated-orcid":false,"given":"Steven M","family":"Markowitz","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1375-4752","authenticated-orcid":false,"given":"Lynda E","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-8975","authenticated-orcid":false,"given":"Michael G","family":"Fradley","sequence":"additional","affiliation":[{"name":"Thalheimer Center for Cardio-Oncology, Division of Cardiology, Department of Medicine, University of Pennsylvania, PA, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-7454","authenticated-orcid":false,"given":"Eric H","family":"Yang","sequence":"additional","affiliation":[{"name":"UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, US"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2023,5,29]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Agarwal MA, Aggarwal A, Rastogi S, et al. Cardiovascular disease burden in cancer patients from 2003 to 2014. Eur Heart J Qual Care Clin Outcomes 2018;4:69\u201370. https:\/\/doi.org\/10.1093\/ehjqcco\/qcx033; PMID:\u00a029045611.","DOI":"10.1093\/ehjqcco\/qcx033"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Guglin M, Aljayeh M, Saiyad S, et al. Introducing a new entity: chemotherapy-induced arrhythmia. Europace 2009;11:1579\u201386. https:\/\/doi.org\/10.1093\/europace\/eup300; PMID:\u00a019801562.","DOI":"10.1093\/europace\/eup300"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Nickel AC, Patel A, Saba NF, et al. Incidence of cancer treatment-induced arrhythmia associated with novel targeted chemotherapeutic agents. J Am Heart Assoc 2018;7:e010101. https:\/\/doi.org\/10.1161\/JAHA.118.010101; PMID:\u00a030371288.","DOI":"10.1161\/jaha.118.010101"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Fradley MG, Beckie TM, Brown SA, et al. Recognition, prevention, and management of arrhythmias and autonomic disorders in cardio-oncology: a scientific statement from the American Heart Association. Circulation 2021;144:e41\u201355. https:\/\/doi.org\/10.1161\/CIR.0000000000000986; PMID:\u00a034134525.","DOI":"10.1161\/cir.0000000000000986"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 2022;43:280\u201399. https:\/\/doi.org\/10.1093\/eurheartj\/ehab674; PMID:\u00a034904661.","DOI":"10.1093\/eurheartj\/ehab674"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Reulen RC, Winter DL, Frobisher C, et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA 2010;304:172\u20139. https:\/\/doi.org\/10.1001\/jama.2010.923; PMID:\u00a020628130.","DOI":"10.1001\/jama.2010.923"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Rock EP, Finkle J, Fingert HJ, et al. Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J 2009;157:827\u201336, 836.e1. https:\/\/doi.org\/10.1016\/j.ahj.2009.02.020; PMID:\u00a019376308.","DOI":"10.1016\/j.ahj.2009.02.020"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Bonsu JM, Kola-Kehinde O, Kim L, et al. Cardiovascular safety communications after US Food and Drug Administration approval of contemporary cancer therapies. JAMA Oncol 2021;7:1722\u20133. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4771; PMID:\u00a034591072.","DOI":"10.1001\/jamaoncol.2021.4771"},{"key":"ref8","unstructured":"European Medicines Agency. ICH E14 Clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: scientific guideline. Amsterdam: European Medicines Agency, 2005. https:\/\/www.ema.europa.eu\/en\/ich-e14-clinical-evaluation-qt-qtc-interval-prolongation-proarrhythmic-potential-non-antiarrhythmic (accessed 29 December 2022)."},{"key":"ref9","unstructured":"US Food and Drug Administration. E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Silver Spring, MD: FDA, 2012. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e14-clinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic-potential-non-antiarrhythmic-0 (accessed 14 March 2023)."},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Giraud EL, Ferrier KRM, Lankheet NAG, et al. The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview. Lancet Oncol 2022;23:e406\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(22)00221-2; PMID:\u00a036055309.","DOI":"10.1016\/s1470-2045(22)00221-2"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Abu Rmilah AA, Lin G, Begna KH, et al. Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. Int J Cancer 2020;147:3160\u20137. https:\/\/doi.org\/10.1002\/ijc.33119; PMID:\u00a032449208.","DOI":"10.1002\/ijc.33119"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Zhang S, Liang F, Tannock I. Use and misuse of common terminology criteria for adverse events in cancer clinical trials. BMC Cancer 2016;16:392. https:\/\/doi.org\/10.1186\/s12885-016-2408-9; PMID:\u00a027377548.","DOI":"10.1186\/s12885-016-2408-9"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Roden DM. A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. Cardiovasc Res 2019;115:895\u2013903. https:\/\/doi.org\/10.1093\/cvr\/cvz013; PMID:\u00a030689740.","DOI":"10.1093\/cvr\/cvz013"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Cheng M, Yang F, Liu J, et al. Tyrosine kinase inhibitors-induced arrhythmias: from molecular mechanisms, pharmacokinetics to therapeutic strategies. Front Cardiovasc Med 2021;8:758010. https:\/\/doi.org\/10.3389\/fcvm.2021.758010; PMID:\u00a034869670.","DOI":"10.3389\/fcvm.2021.758010"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Varterasian M, Meyer M, Fingert H, et al. Baseline heart rate-corrected QT and eligibility for clinical trials in oncology. J Clin Oncol 2003;21:3378\u20139. https:\/\/doi.org\/10.1200\/JCO.2003.99.104; PMID:\u00a012947082.","DOI":"10.1200\/jco.2003.99.104"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Borad MJ, Soman AD, Benjamin M, et al. Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials. Investig New Drugs 2013;31:1056\u201365. https:\/\/doi.org\/10.1007\/s10637-012-9909-4; PMID:\u00a023242862.","DOI":"10.1007\/s10637-012-9909-4"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Vandenberk B, Vandael E, Robyns T, et al. Which QT correction formulae to use for QT monitoring? J Am Heart Assoc 2016;5:e003264. https:\/\/doi.org\/10.1161\/JAHA.116.003264; PMID:\u00a027317349.","DOI":"10.1161\/jaha.116.003264"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Sagar S, Liu PP, Cooper LT. Myocarditis. Lancet 2012;379:738\u201347. https:\/\/doi.org\/10.1016\/S0140-6736(11)60648-X; PMID:\u00a022185868.","DOI":"10.1016\/S0140-6736(11)60648-X"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Mladosievicova B, Foltinova A, Luptak I, et al. Frequency-domain analysis of the QRS complex after treatment of childhood cancer with anthracycline cytostatics. Pediatr Cardiol 2001;22:478\u201382. https:\/\/doi.org\/10.1007\/s002460010278; PMID:\u00a011894149.","DOI":"10.1007\/s002460010278"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Zlotoff DA, Hassan MZO, Zafar A, et al. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer 2021;9:e002007. https:\/\/doi.org\/10.1136\/jitc-2020-002007; PMID:\u00a033653803.","DOI":"10.1136\/jitc-2020-002007"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473\u201382. https:\/\/doi.org\/10.1056\/NEJMra000650; PMID:\u00a011794197.","DOI":"10.1056\/nejmra000650"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Jain R, Singh R, Yamini S, Das MK. Fragmented ECG as a risk marker in cardiovascular diseases. Curr Cardiol Rev 2014;10:277\u201386. https:\/\/doi.org\/10.2174\/1573403X10666140514103451; PMID:\u00a024827794.","DOI":"10.2174\/1573403x10666140514103451"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Liang X, Wang Y, Yin X, et al. Electrocardiographic characteristics of breast cancer patients treated with chemotherapy. Cardiol Res Pract 2020;2020:6678503. https:\/\/doi.org\/10.1155\/2020\/6678503; PMID:\u00a033376602.","DOI":"10.1155\/2020\/6678503"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Gurdogan M, Ozkan U. A novel predictor of chemotherapeutic cardiotoxicity in patients with non-Hodgkin lymphoma. Oncol Res Treat 2019;42:375\u201381. https:\/\/doi.org\/10.1159\/000500439; PMID:\u00a031132772.","DOI":"10.1159\/000500439"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Adar A, Cany\u0131lmaz E, Kiris A, et al. Radiotherapy induces development of fragmented QRS in patients with breast cancer. Breast Care (Basel) 2015;10:277\u201380. https:\/\/doi.org\/10.1159\/000431030; PMID:\u00a026600765.","DOI":"10.1159\/000431030"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Salem JE, Nguyen LS, Moslehi JJ, et al. Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. Eur Heart J 2021;42:3915\u201328. https:\/\/doi.org\/10.1093\/eurheartj\/ehab362; PMID:\u00a034370839.","DOI":"10.1093\/eurheartj\/ehab362"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Salem JE, Manouchehri A, Bretagne M, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol 2019;74:1667\u201378. https:\/\/doi.org\/10.1016\/j.jacc.2019.07.056; PMID:\u00a031558250.","DOI":"10.1016\/j.jacc.2019.07.056"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Naing A, Veasey-Rodrigues H, Hong DS, et al. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol 2012;23:2960\u20133. https:\/\/doi.org\/10.1093\/annonc\/mds130; PMID:\u00a022745218.","DOI":"10.1093\/annonc\/mds130"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Anker MS, von Haehling S, Coats AJS, et al. Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study. Eur J Heart Fail 2021;23:145\u201353. https:\/\/doi.org\/10.1002\/ejhf.2059; PMID:\u00a033222388.","DOI":"10.1002\/ejhf.2059"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Jayaprakash S. Clinical presentations, diagnosis, and management of arrhythmias associated with cardiac tumors. J Arrhythm 2018;34:384\u201393. https:\/\/doi.org\/10.1002\/joa3.12030; PMID:\u00a030167009.","DOI":"10.1002\/joa3.12030"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Feng Z, Philipson D, Uzzell JP, et al. A case of ventricular tachycardia caused by a rare cardiac mesenchymal hamartoma. JACC Case Rep 2020;2:1049\u201355. https:\/\/doi.org\/10.1016\/j.jaccas.2020.04.038; PMID:\u00a034317413.","DOI":"10.1016\/j.jaccas.2020.04.038"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Cina SJ, Smialek JE, Burke AP, et al. Primary cardiac tumors causing sudden death: a review of the literature. Am J Forensic Med Pathol 1996;17:271\u201381. https:\/\/doi.org\/10.1097\/00000433-199612000-00001; PMID:\u00a08947350.","DOI":"10.1097\/00000433-199612000-00001"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Myers KA, Wong KK, Tipple M, Sanatani S. Benign cardiac tumours, malignant arrhythmias. Can J Cardiol 2010;26:e58\u201361. https:\/\/doi.org\/10.1016\/S0828-282X(10)70009-X; PMID:\u00a020151061.","DOI":"10.1016\/s0828-282x(10)70009-x"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852\u201360. https:\/\/doi.org\/10.1200\/JCO.2001.19.18.3852; PMID:\u00a011559723.","DOI":"10.1200\/jco.2001.19.18.3852"},{"key":"ref35","unstructured":"Yeh ETH (ed). MD Anderson practices in onco-cardiology. Houston, TX: The University of Texas MD Anderson Cancer Center, 2016."},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Kumazaki M, Ando H, Kakei M, et al. \u03b1-lipoic acid protects against arsenic trioxide-induced acute QT prolongation in anesthetized guinea pigs. Eur J Pharmacol 2013;705:1\u201310. https:\/\/doi.org\/10.1016\/j.ejphar.2013.02.027; PMID:\u00a023474023.","DOI":"10.1016\/j.ejphar.2013.02.027"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Badri M, Patel A, Patel C, et al. Mexiletine prevents recurrent torsades de pointes in acquired long QT syndrome refractory to conventional measures. JACC Clin Electrophysiol 2015;1:315\u201322. https:\/\/doi.org\/10.1016\/j.jacep.2015.05.008; PMID:\u00a029759319.","DOI":"10.1016\/j.jacep.2015.05.008"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Arbel Y, Swartzon M, Justo D. QT prolongation and torsades de pointes in patients previously treated with anthracyclines. Anti Cancer Drugs 2007;18:493\u20138. https:\/\/doi.org\/10.1097\/CAD.0b013e328012d023; PMID:\u00a017351403.","DOI":"10.1097\/cad.0b013e328012d023"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Galetta F, Franzoni F, Cervetti G, et al. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed Pharmacother 2005;59:541\u20134. https:\/\/doi.org\/10.1016\/j.biopha.2004.12.003; PMID:\u00a016325366.","DOI":"10.1016\/j.biopha.2004.12.003"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Buza V, Rajagopalan B, Curtis AB. Cancer treatment-induced arrhythmias: focus on chemotherapy and targeted therapies. Circ Arrhythm Electrophysiol 2017;10:e005443. https:\/\/doi.org\/10.1161\/CIRCEP.117.005443; PMID:\u00a028798022.","DOI":"10.1161\/circep.117.005443"},{"key":"ref41","unstructured":"Horacek JM, Jakl M, Horackova J, et al. Assessment of anthracycline-induced cardiotoxicity with electrocardiography. Exp Oncol 2009;31:115\u20137. PMID:\u00a019550402."},{"key":"ref42","unstructured":"Iwata N, Karasawa M, Omine M, et al. Aclarubicin-associated QTc prolongation and ventricular fibrillation. Cancer Treat Rep 1984;68:527\u20139. PMID:\u00a06584207."},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Kilickap S, Barista I, Akgul E, et al. Early and late arrhythmogenic effects of doxorubicin. South Med J 2007;100:262\u20135. https:\/\/doi.org\/10.1097\/01.smj.0000257382.89910.fe; PMID:\u00a017396729.","DOI":"10.1097\/01.smj.0000257382.89910.fe"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Dural M, Demir L, Babayi\u011fit E, et al. Fragmented QRS formation and its predictors in patients with breast cancer receiving anthracycline-based chemotherapy. J Electrocardiol 2019;54:5\u20139. https:\/\/doi.org\/10.1016\/j.jelectrocard.2019.02.003; PMID:\u00a030782548.","DOI":"10.1016\/j.jelectrocard.2019.02.003"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Chen Z, Lu K, Zhou L, et al. Electrocardiographic characteristics of diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy. J Electrocardiol 2020;60:195\u20139. https:\/\/doi.org\/10.1016\/j.jelectrocard.2020.04.024; PMID:\u00a032413696.","DOI":"10.1016\/j.jelectrocard.2020.04.024"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Mazur M, Wang F, Hodge DO, et al. Burden of cardiac arrhythmias in patients with anthracycline-related cardiomyopathy. JACC Clin Electrophysiol 2017;3:139\u201350. https:\/\/doi.org\/10.1016\/j.jacep.2016.08.009; PMID:\u00a029759386.","DOI":"10.1016\/j.jacep.2016.08.009"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Ducroq J, Moha ou Maati H, Guilbot S, et al. Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks). Br J Pharmacol 2010;159:93\u2013101. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00371.x; PMID:\u00a019703166.","DOI":"10.1111\/j.1476-5381.2009.00371.x"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Yilmaz U, Oztop I, Ciloglu A, et al. 5-fluorouracil increases the number and complexity of premature complexes in the heart: a prospective study using ambulatory ECG monitoring. Int J Clin Pract 2007;61:795\u2013801. https:\/\/doi.org\/10.1111\/j.1742-1241.2007.01323.x; PMID:\u00a017493091.","DOI":"10.1111\/j.1742-1241.2007.01323.x"},{"key":"ref49","unstructured":"Khan MA, Masood N, Husain N, et al. A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital and Research Center. J Pak Med Assoc 2012;62:430\u20134. PMID:\u00a022755303."},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Rathkopf DE, Picus J, Hussain A, et al. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 2013;72:537\u201344. https:\/\/doi.org\/10.1007\/s00280-013-2224-8; PMID:\u00a023820963.","DOI":"10.1007\/s00280-013-2224-8"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Shah MH, Binkley P, Chan K, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006;12:3997\u20134003. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2689; PMID:\u00a016818698.","DOI":"10.1158\/1078-0432.ccr-05-2689"},{"key":"ref52","unstructured":"DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 2018;378:2386\u201398. https:\/\/doi.org\/10.1056\/NEJMoa1716984; PMID:\u00a029860938."},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Tomcs\u00e1nyi J, N\u00e9nyei Z, M\u00e1trai Z, B\u00f3zsik B. Ibrutinib, an approved tyrosine kinase inhibitor as a potential cause of recurrent polymorphic ventricular tachycardia. JACC Clin Electrophysiol 2016;2:847\u20139. https:\/\/doi.org\/10.1016\/j.jacep.2016.07.004; PMID:\u00a029759770.","DOI":"10.1016\/j.jacep.2016.07.004"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Guha A, Armanious M, Fradley MG. Update on cardio-oncology: novel cancer therapeutics and associated cardiotoxicities. Trends Cardiovasc Med 2019;29:29\u201339. https:\/\/doi.org\/10.1016\/j.tcm.2018.06.001; PMID:\u00a029910109.","DOI":"10.1016\/j.tcm.2018.06.001"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 2013;36:295\u2013316. https:\/\/doi.org\/10.1007\/s40264-013-0047-5; PMID:\u00a023620167.","DOI":"10.1007\/s40264-013-0047-5"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Spechbach H, Morel P, Ing Lorenzini K, et al. Reversible ventricular arrythmia induced by dasatinib. Clin Case Rep 2013;1:20\u20135. https:\/\/doi.org\/10.1002\/ccr3.5; PMID:\u00a025356203.","DOI":"10.1002\/ccr3.5"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLOS ONE 2012;7:e30353. https:\/\/doi.org\/10.1371\/journal.pone.0030353; PMID:\u00a022363427.","DOI":"10.1371\/journal.pone.0030353"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Guha A, Derbala MH, Zhao Q, et al. Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies. J Am Coll Cardiol 2018;72:697\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2018.06.002; PMID:\u00a030072003.","DOI":"10.1016\/j.jacc.2018.06.002"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood 2017;129:2581\u20134. https:\/\/doi.org\/10.1182\/blood-2016-10-742437; PMID:\u00a028223277.","DOI":"10.1182\/blood-2016-10-742437"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Bhat SA, Gambril J, Azali L, et al. Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Blood 2022;140:2142\u20135. https:\/\/doi.org\/10.1182\/blood.2022016953; PMID:\u00a035917449.","DOI":"10.1182\/blood.2022016953"},{"key":"ref61","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016;375:1738\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1609709; PMID:\u00a027717303."},{"key":"ref62","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA-approved drugs. 2023. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/ (accessed 14 March 2023)."},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018;71:1755\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037; PMID:\u00a029567210.","DOI":"10.1016\/S0735-1097(18)31240-3"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Power JR, Alexandre J, Choudhary A, et al. Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis. Circulation 2021;144:1521\u20133. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.055816; PMID:\u00a034723640.","DOI":"10.1161\/CIR.0000000000001042"},{"key":"ref65","unstructured":"Escudier M, Cautela J, Malissen N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 2017;136:2085\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030571; PMID:\u00a029158217."},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Stein-Merlob AF, Hsu JJ, Colton B, et al. Keeping immune checkpoint inhibitor myocarditis in check: advanced circulatory mechanical support as a bridge to recovery. ESC Heart Fail 2021;8:4301\u20136. https:\/\/doi.org\/10.1002\/ehf2.13545; PMID:\u00a034390221.","DOI":"10.1002\/ehf2.13545"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Mir H, Alhussein M, Alrashidi S, et al. Cardiac complications associated with checkpoint inhibition: a systematic review of the literature in an important emerging area. Can J Cardiol 2018;34:1059\u201368. https:\/\/doi.org\/10.1016\/j.cjca.2018.03.012; PMID:\u00a029980467.","DOI":"10.1016\/j.cjca.2018.03.012"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Rubio-Infante N, Ram\u00edrez-Flores YA, Castillo EC, et al. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail 2021;23:1739\u201347. https:\/\/doi.org\/10.1002\/ejhf.2289; PMID:\u00a034196077.","DOI":"10.1002\/ejhf.2289"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Goldman A, Maor E, Bomze D, et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J Am Coll Cardiol 2021;78:1800\u201313. https:\/\/doi.org\/10.1016\/j.jacc.2021.08.044; PMID:\u00a034711339.","DOI":"10.1016\/j.jacc.2021.08.044"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Thotamgari SR, Grewal US, Nobel Bhuiyan MA, et al. The association of cardiac arrhythmias with chimeric antigen receptor T cell therapy in hospitalised patients: insights from National Inpatient Sample. Eur J Cancer 2022;174:131\u20133. https:\/\/doi.org\/10.1016\/j.ejca.2022.07.019; PMID:\u00a035994793.","DOI":"10.1016\/j.ejca.2022.07.019"},{"key":"ref71","unstructured":"CredibleMeds. Home. 2022. https:\/\/crediblemeds.org (accessed 29 December 2022)."},{"key":"ref72","unstructured":"US Food and Drug Administration. MedWatch forms for FDA safety reporting. 2022. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/medwatch-forms-fda-safety-reporting (accessed 14 March 2023)."},{"key":"ref73","unstructured":"Uppsala Monitoring Centre. About VigiBase. 2022. https:\/\/who-umc.org\/vigibase\/ (accessed 14 March 2023)."},{"key":"ref74","unstructured":"US Food and Drug Administration. FDA adverse event reporting systems (FAERS) public dashboard. 2022. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard (accessed 14 March 2023)."},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Porta-S\u00e1nchez A, Gilbert C, Spears D, et al. Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc 2017;6:e007724. https:\/\/doi.org\/10.1161\/JAHA.117.007724; PMID:\u00a029217664.","DOI":"10.1161\/jaha.117.007724"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Keren A, Tzivoni D, Gavish D, et al. Etiology, warning signs and therapy of torsade de pointes. A study of 10 patients. Circulation 1981;64:1167\u201374. https:\/\/doi.org\/10.1161\/01.cir.64.6.1167; PMID:\u00a07296791.","DOI":"10.1161\/01.cir.64.6.1167"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Miyake CY, Del Nido PJ, Alexander ME, et al. Cardiac tumors and associated arrhythmias in pediatric patients, with observations on surgical therapy for ventricular tachycardia. J Am Coll Cardiol 2011;58:1903\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2011.08.005; PMID:\u00a022018302.","DOI":"10.1016\/j.jacc.2011.08.005"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Mohamed MO, Barac A, Contractor T, et al. Prevalence and in-hospital outcomes of patients with malignancies undergoing de novo cardiac electronic device implantation in the USA. Europace 2020;22:1083\u201396. https:\/\/doi.org\/10.1093\/europace\/euaa087; PMID:\u00a032361739.","DOI":"10.1093\/europace\/euaa087"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines and the Heart Rhythm Society. Circulation 2018;138:e210\u201371. https:\/\/doi.org\/10.1161\/CIR.0000000000000548; PMID:\u00a029084733.","DOI":"10.1161\/CIR.0000000000000615"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Singh JP, Solomon SD, Fradley MG, et al. Association of cardiac resynchronization therapy with change in left ventricular ejection fraction in patients with chemotherapy-induced cardiomyopathy. JAMA 2019;322:1799\u2013805. https:\/\/doi.org\/10.1001\/jama.2019.16658; PMID:\u00a031714987.","DOI":"10.1001\/jama.2019.16658"}],"container-title":["Arrhythmia &amp; Electrophysiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aerjournal.com\/articleindex\/aer.2023.04","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T13:50:05Z","timestamp":1685454605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerjournal.com\/articleindex\/aer.2023.04"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,29]]},"references-count":81,"URL":"https:\/\/doi.org\/10.15420\/aer.2023.04","relation":{},"ISSN":["2050-3377","2050-3369"],"issn-type":[{"value":"2050-3377","type":"electronic"},{"value":"2050-3369","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,29]]},"article-number":"e16"}}